B7-H3 × CD3

FDA slaps partial hold on MacroGenics for bispecific cancer trials as liver tox spurs safety fears
Endpoints
Mon, 12/10/18 - 09:52 am
Macrogenics
FDA
bispecific antibodies
clinical trials
B7-H3 × CD3